TGF-β as a therapeutic target in the infarcted and failing heart: cellular mechanisms, challenges, and opportunities

References

• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (Esc)developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–2200. doi: 10.1093/eurheartj/ehw128
   PubMed Web of Science ®Google Scholar
• Schwinger RHG. Pathophysiology of heart failure. Cardiovasc Diagn Ther. 2021;11(1):263–76. doi: 10.21037/cdt-20-302
   PubMed Web of Science ®Google Scholar
• Savarese G, Stolfo D, Sinagra G, et al. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol. 2022;19(2):100–16. doi: 10.1038/s41569-021-00605-5
   PubMed Web of Science ®Google Scholar
• Frangogiannis NG. Cardiac fibrosis. Cardiovasc Res. 2021;117(6):1450–88. doi: 10.1093/cvr/cvaa324
   PubMed Web of Science ®Google Scholar
• Frangogiannis NG. Transforming growth factor–β in tissue fibrosis. J Exp Med. 2020;217(3):e20190103. doi: 10.1084/jem
   PubMed Web of Science ®Google Scholar
• Lodyga M, Hinz B. TGF-beta1 - a truly transforming growth factor in fibrosis and immunity. Semin Cell Dev Biol. 2020;101:123–139. doi: 10.1016/j.semcdb.2019.12.010
   PubMed Web of Science ®Google Scholar
• Massague J, Sheppard D. TGF-β signaling in health and disease. Cell. 2023;186(19):4007–4037. doi: 10.1016/j.cell.2023.07.036
   PubMed Web of Science ®Google Scholar
• Koitabashi N, Danner T, Zaiman AL, et al. Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload. J Clin Invest. 2011;121(6):2301–2312. doi: 10.1172/JCI44824
   PubMed Web of Science ®Google Scholar
• Chen B, Huang S, Su Y, et al. Macrophage Smad3 protects the infarcted heart, stimulating phagocytosis and regulating inflammation. Circ Res. 2019;125(1):55–70. doi: 10.1161/CIRCRESAHA.119.315069
   PubMed Web of Science ®Google Scholar
• Goumans MJ, Ten Dijke P. TGF-β Signaling in Control of Cardiovascular Function. Cold Spring Harb Perspect Biol. 2018;10(2):10. doi: 10.1101/cshperspect.a022210
   Web of Science ®Google Scholar
• Hinck AP, Mueller TD, Springer TA. Structural biology and evolution of the TGF-β family. Cold Spring Harb Perspect Biol. 2016;8(12):a022103. doi: 10.1101/cshperspect.a022103
   PubMed Web of Science ®Google Scholar
• Lyons RM, Keski-Oja J, Moses HL. Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J Cell Bio. 1988;106(5):1659–65. doi: 10.1083/jcb.106.5.1659
   PubMed Web of Science ®Google Scholar
• Khalil N, Corne S, Whitman C, et al. Plasmin regulates the activation of cell-associated latent TGF-beta 1 secreted by rat alveolar macrophages after in vivo bleomycin injury. Am J Respir Cell Mol Biol. 1996;15(2):252–9. doi: 10.1165/ajrcmb.15.2.8703482
   PubMed Web of Science ®Google Scholar
• Guo M, Mathieu PA, Linebaugh B, et al. Phorbol ester activation of a proteolytic cascade capable of activating latent transforming growth factor-β. J Biol Chem. 2002;277(17):14829–14837. doi: 10.1074/jbc.M108180200
   PubMed Web of Science ®Google Scholar
• Yao Y, Hu C, Song Q, et al. ADAMTS16 activates latent TGF-β, accentuating fibrosis and dysfunction of the pressure-overloaded heart. Cardiovasc Res. 2019;116(5):956–969. doi: 10.1093/cvr/cvz187
   Web of Science ®Google Scholar
• Munger JS, Huang X, Kawakatsu H, et al. A mechanism for regulating pulmonary inflammation and fibrosis: the Integrin αvβ6 binds and activates latent TGF β1. Cell. 1999;96(3):319–328. doi: 10.1016/S0092-8674(00)80545-0
   PubMed Web of Science ®Google Scholar
• Hakkinen L, Koivisto L, Gardner H, et al. Increased expression of β6-integrin in skin leads to spontaneous development of chronic wounds. Am J Pathol. 2004;164(1):229–242. doi: 10.1016/S0002-9440(10)63113-6
   PubMed Web of Science ®Google Scholar
• Sarrazy V, Koehler A, Chow ML, et al. Integrins αvβ5 and αvβ3 promote latent TGF-β1 activation by human cardiac fibroblast contraction. Cardiovasc Res. 2014;102(3):407–417. doi: 10.1093/cvr/cvu053
   PubMed Web of Science ®Google Scholar
• Klingberg F, Chau G, Walraven M, et al. The fibronectin ED-A domain enhances recruitment of latent TGF-beta-binding protein-1 to the fibroblast matrix. J Cell Sci. 2018:131. doi: 10.1242/jcs.201293
   Web of Science ®Google Scholar
• Serini G, Bochaton-Piallat ML, Ropraz P, et al. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-β1. J Cell Bio. 1998;142(3):873–881. doi: 10.1083/jcb.142.3.873
   PubMed Web of Science ®Google Scholar
• Robertson IB, Rifkin DB. Regulation of the bioavailability of TGF-β and TGF-β-related proteins. Cold Spring Harb Perspect Biol. 2016;8(6):a021907. doi: 10.1101/cshperspect.a021907
   PubMed Web of Science ®Google Scholar
• Massague J. How cells read TGF-β signals. Nat Rev Mol Cell Biol. 2000;1(3):169–178. doi: 10.1038/35043051
   PubMed Web of Science ®Google Scholar
• Heldin CH, Moustakas A. Signaling receptors for TGF-β family members. Cold Spring Harb Perspect Biol. 2016;8(8):a022053. doi: 10.1101/cshperspect.a022053
   PubMed Web of Science ®Google Scholar
• Goumans MJ, Valdimarsdottir G, Itoh S, et al. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J. 2002;21(7):1743–1753. doi: 10.1093/emboj/21.7.1743
   PubMed Web of Science ®Google Scholar
• Oh SP, Seki T, Goss KA, et al. Activin receptor-like kinase 1 modulates transforming growth factor-β1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci U S A. 2000;97(6):2626–2631. doi: 10.1073/pnas.97.6.2626
   PubMed Web of Science ®Google Scholar
• Goumans MJ, Valdimarsdottir G, Itoh S, et al. Activin Receptor-like Kinase (ALK)1 is an antagonistic mediator of lateral TGFβ/ALK5 signaling. Mol Cell. 2003;12(4):817–828. doi: 10.1016/S1097-2765(03)00386-1
   PubMed Web of Science ®Google Scholar
• Nurgazieva D, Mickley A, Moganti K, et al. TGF-β1, but not bone morphogenetic proteins, activates Smad1/5 pathway in primary human macrophages and induces expression of proatherogenic genes. J Immunol. 2015;194(2):709–718. doi: 10.4049/jimmunol.1300272
   PubMed Web of Science ®Google Scholar
• Zhang H, Du L, Zhong Y, et al. Transforming growth factor-β stimulates Smad1/5 signaling in pulmonary artery smooth muscle cells and fibroblasts of the newborn mouse through ALK1. Am J Physiol Lung Cell Mol Physiol. 2017;313(3):L615–L27. doi: 10.1152/ajplung.00079.2017
   PubMed Web of Science ®Google Scholar
• Feng XH, Derynck R. SPECIFICITY AND VERSATILITY IN TGF-β SIGNALING THROUGH SMADS. Annu Rev Cell Dev Biol. 2005;21(1):659–693. doi: 10.1146/annurev.cellbio.21.022404.142018
   PubMed Web of Science ®Google Scholar
• Imamura T, Takase M, Nishihara A, et al. Smad6 inhibits signalling by the TGF-β superfamily. Nature. 1997;389(6651):622–626. doi: 10.1038/39355
   PubMed Web of Science ®Google Scholar
• Nakao A, Afrakhte M, Moren A, et al. Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling. Nature. 1997;389(6651):631–635. doi: 10.1038/39369
   PubMed Web of Science ®Google Scholar
• Morikawa M, Derynck R, Miyazono K. TGF-β and the TGF-β family: context-dependent roles in cell and tissue physiology. Cold Spring Harb Perspect Biol. 2016;8(5):8. doi: 10.1101/cshperspect.a021873
   Web of Science ®Google Scholar
• Humeres C, Shinde AV, Hanna A, et al. Smad7 effects on TGF-β and ErbB2 restrain myofibroblast activation and protect from postinfarction heart failure. J Clin Investigation. 2022;132(3):e146926. doi: 10.1172/JCI
   PubMed Web of Science ®Google Scholar
• Funaba M, Zimmerman CM, Mathews LS. Modulation of Smad2-mediated signaling by extracellular signal-regulated kinase. J Biol Chem. 2002;277(44):41361–8. doi: 10.1074/jbc.M204597200
   PubMed Web of Science ®Google Scholar
• Kretzschmar M, Doody J, Timokhina I, et al. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev. 1999;13(7):804–16. doi: 10.1101/gad.13.7.804
   PubMed Web of Science ®Google Scholar
• Furukawa F, Matsuzaki K, Mori S, et al. p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology. 2003;38(4):879–89. doi: 10.1002/hep.1840380414
   PubMed Web of Science ®Google Scholar
• Yoshida K, Matsuzaki K, Mori S, et al. Transforming growth factor-β and platelet-derived growth factor signal via c-jun N-Terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury. Am J Pathol. 2005;166(4):1029–1039. doi: 10.1016/S0002-9440(10)62324-3
   PubMed Web of Science ®Google Scholar
• Seay U, Sedding D, Krick S, et al. Transforming growth factor-β-dependent growth inhibition in primary vascular smooth muscle cells is p38-dependent. J Pharmacol Exp Ther. 2005;315(3):1005–1012. doi: 10.1124/jpet.105.091249
   PubMed Web of Science ®Google Scholar
• Schwartze JT, Becker S, Sakkas E, et al. Glucocorticoids recruit Tgfbr3 and Smad1 to shift transforming growth factor-β signaling from the Tgfbr1/Smad2/3 axis to the Acvrl1/Smad1 axis in lung fibroblasts. J Biol Chem. 2014;289(6):3262–3275. doi: 10.1074/jbc.M113.541052
   PubMed Web of Science ®Google Scholar
• Lebrin F, Goumans MJ, Jonker L, et al. Endoglin promotes endothelial cell proliferation and TGF-β/ALK1 signal transduction. EMBO J. 2004;23(20):4018–4028. doi: 10.1038/sj.emboj.7600386
   PubMed Web of Science ®Google Scholar
• Duncan MR, Frazier KS, Abramson S, et al. Connective tissue growth factor mediates transforming growth factor β-induced collagen synthesis: down-regulation by cAMP. FASEB J. 1999;13(13):1774–1786. doi: 10.1096/fasebj.13.13.1774
   PubMed Web of Science ®Google Scholar
• Abreu JG, Ketpura NI, Reversade B, et al. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-β. Nat Cell Biol. 2002;4(8):599–604. doi: 10.1038/ncb826
   PubMed Web of Science ®Google Scholar
• Mori T, Kawara S, Shinozaki M, et al. Role and interaction of connective tissue growth factor with transforming growth factor-? in persistent fibrosis: a mouse fibrosis model. J Cell Physiol. 1999;181(1):153–159. doi: 10.1002/(SICI)1097-4652(199910)181:1<153:AID-JCP16>3.0.CO;2-K
   PubMed Web of Science ®Google Scholar
• Schafer S, Viswanathan S, Widjaja AA, et al. IL-11 is a crucial determinant of cardiovascular fibrosis. Nature. 2017;552(7683):110–5. doi: 10.1038/nature24676
   PubMed Web of Science ®Google Scholar
• Wahl SM, Allen JB, Weeks BS, et al. Transforming growth factor beta enhances integrin expression and type IV collagenase secretion in human monocytes. Proc Natl Acad Sci U S A. 1993;90(10):4577–81. doi: 10.1073/pnas.90.10.4577
   PubMed Web of Science ®Google Scholar
• Wahl SM, Hunt DA, Wakefield LM, et al. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci U S A. 1987;84(16):5788–92. doi: 10.1073/pnas.84.16.5788
   PubMed Web of Science ®Google Scholar
• Basoni C, Nobles M, Grimshaw A, et al. Inhibitory control of TGF-β1 on the activation of Rap1, CD11b, and transendothelial migration of leukocytes. FASEB J. 2005;19(7):822–824. doi: 10.1096/fj.04-3085fje
   PubMedGoogle Scholar
• Kitamura M, Suto T, Yokoo T, et al. Transforming growth factor-beta 1 is the predominant paracrine inhibitor of macrophage cytokine synthesis produced by glomerular mesangial cells. J Immunol. 1996;156(8):2964–71. doi: 10.4049/jimmunol.156.8.2964
   PubMed Web of Science ®Google Scholar
• Fantini MC, Becker C, Monteleone G, et al. Cutting edge: TGF-β induces a regulatory phenotype in CD4+CD25− T cells through Foxp3 induction and down-regulation of Smad7. J Immunol. 2004;172(9):5149–5153. doi: 10.4049/jimmunol.172.9.5149
   PubMed Web of Science ®Google Scholar
• Deten A, Holzl A, Leicht M, et al. Changes in extracellular matrix and in transforming growth factor beta isoforms after coronary artery ligation in rats. J Mol Cell Cardiol. 2001;33(6):1191–207. doi: 10.1006/jmcc.2001.1383
   PubMed Web of Science ®Google Scholar
• Dewald O, Ren G, Duerr GD, et al. Of mice and dogs: species-specific differences in the inflammatory response following myocardial infarction. Am J Pathol. 2004;164(2):665–77. doi: 10.1016/S0002-9440(10)63154-9
   PubMed Web of Science ®Google Scholar
• Xia Y, Lee K, Li N, et al. Characterization of the inflammatory and fibrotic response in a mouse model of cardiac pressure overload. Histochem Cell Biol. 2009;131(4):471–81. doi: 10.1007/s00418-008-0541-5
   PubMed Web of Science ®Google Scholar
• Takahashi N, Calderone A, Izzo NJ Jr., et al. Hypertrophic stimuli induce transforming growth factor-beta 1 expression in rat ventricular myocytes. J Clin Invest. 1994;94(4):1470–6. doi: 10.1172/JCI117485
   PubMed Web of Science ®Google Scholar
• Reddy S, Zhao M, Hu DQ, et al. Physiologic and molecular characterization of a murine model of right ventricular volume overload. Am J Physiol Heart Circ Physiol. 2013;304(10):H1314–27. doi: 10.1152/ajpheart.00776.2012
   PubMed Web of Science ®Google Scholar
• Teekakirikul P, Eminaga S, Toka O, et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires tgf-β. J Clin Invest. 2010;120(10):3520–3529. doi: 10.1172/JCI42028
   PubMed Web of Science ®Google Scholar
• Bhandary B, Meng Q, James J, et al. Cardiac Fibrosis in Proteotoxic Cardiac Disease is Dependent Upon Myofibroblast TGF-β Signaling. J Am Heart Assoc. 2018;7(20):e010013. doi: 10.1161/JAHA.118.010013
   PubMed Web of Science ®Google Scholar
• Kania G, Blyszczuk P, Stein S, et al. Heart-infiltrating prominin-1 + /CD133 + progenitor cells represent the cellular source of transforming growth factor β–mediated cardiac fibrosis in experimental autoimmune myocarditis. Circ Res. 2009;105(5):462–470. doi: 10.1161/CIRCRESAHA.109.196287
   PubMed Web of Science ®Google Scholar
• Biernacka A, Cavalera M, Wang J, et al. Smad3 signaling promotes fibrosis while preserving cardiac and aortic geometry in obese diabetic mice. Circ Heart Fail. 2015;8(4):788–98. doi: 10.1161/CIRCHEARTFAILURE.114.001963
   PubMed Web of Science ®Google Scholar
• Pauschinger M, Knopf D, Petschauer S, et al. Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation. 1999;99(21):2750–6. doi: 10.1161/01.CIR.99.21.2750
   PubMed Web of Science ®Google Scholar
• Felkin LE, Lara-Pezzi E, George R, et al. Expression of extracellular matrix genes during myocardial recovery from heart failure after left ventricular assist device support. J Heart Lung Transplant. 2009;28(2):117–122. doi: 10.1016/j.healun.2008.11.910
   PubMed Web of Science ®Google Scholar
• Khan S, Joyce J, Margulies KB, et al. Enhanced bioactive myocardial transforming growth factor-β in advanced human heart failure. Circ J. 2014;78(11):2711–2718. doi: 10.1253/circj.CJ-14-0511
   PubMed Web of Science ®Google Scholar
• Li RK, Li G, Mickle DA, et al. Overexpression of transforming growth factor-β1 and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy. Circulation. 1997;96(3):874–881. doi: 10.1161/01.CIR.96.3.874
   PubMed Web of Science ®Google Scholar
• Nagaraju CK, Robinson EL, Abdesselem M, et al. Myofibroblast phenotype and reversibility of fibrosis in patients with end-stage heart failure. J Am Coll Cardiol. 2019;73(18):2267–82. doi: 10.1016/j.jacc.2019.02.049
   PubMed Web of Science ®Google Scholar
• Bielecka-Dabrowa A, Sakowicz A, Misztal M, et al. Differences in biochemical and genetic biomarkers in patients with heart failure of various etiologies. Int J Cardiol. 2016;221:1073–80. doi: 10.1016/j.ijcard.2016.07.150
   PubMed Web of Science ®Google Scholar
• Tomita H, Egashira K, Ohara Y, et al. Early induction of transforming growth factor-β via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension. 1998;32(2):273–279. doi: 10.1161/01.HYP.32.2.273
   PubMed Web of Science ®Google Scholar
• Dewald O, Zymek P, Winkelmann K, et al. CCL2/Monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res. 2005;96(8):881–9. doi: 10.1161/01.RES.0000163017.13772.3a
   PubMed Web of Science ®Google Scholar
• Abe M, Oda N, Sato Y. Cell-associated activation of latent transforming growth factor-β by calpain. J Cell Physiol. 1998;174(2):186–193. doi: 10.1002/(SICI)1097-4652(199802)174:2<186:AID-JCP6>3.0.CO;2-K
   PubMed Web of Science ®Google Scholar
• Maeda S, Dean DD, Gomez R, et al. The first stage of transforming growth factor β1 activation is release of the large latent complex from the extracellular matrix of growth plate chondrocytes by matrix vesicle stromelysin-1 (MMP-3). Calcif Tissue Int. 2002;70(1):54–65. doi: 10.1007/s002230010032
   PubMed Web of Science ®Google Scholar
• Bourd-Boittin K, Bonnier D, Leyme A, et al. Protease profiling of liver fibrosis reveals the ADAM metallopeptidase with thrombospondin type 1 motif, 1 as a central activator of transforming growth factor beta. Hepatology. 2011;54(6):2173–84. doi: 10.1002/hep.24598
   PubMed Web of Science ®Google Scholar
• Frangogiannis NG, Ren G, Dewald O, et al. Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts. Circulation. 2005;111(22):2935–2942. doi: 10.1161/CIRCULATIONAHA.104.510354
   PubMed Web of Science ®Google Scholar
• Xia Y, Dobaczewski M, Gonzalez-Quesada C, et al. Endogenous thrombospondin 1 protects the pressure-overloaded myocardium by modulating fibroblast phenotype and matrix metabolism. Hypertension. 2011;58(5):902–11. doi: 10.1161/HYPERTENSIONAHA.111.175323
   PubMed Web of Science ®Google Scholar
• Gonzalez-Quesada C, Cavalera M, Biernacka A, et al. Thrombospondin-1 induction in the diabetic myocardium stabilizes the cardiac matrix in addition to promoting vascular rarefaction through angiopoietin-2 upregulation. Circ Res. 2013;113(12):1331–44. doi: 10.1161/CIRCRESAHA.113.302593
   PubMed Web of Science ®Google Scholar
• Schultz-Cherry S, Ribeiro S, Gentry L, et al. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system. J Biol Chem. 1994;269(43):26775–82. doi: 10.1016/S0021-9258(18)47086-X
   PubMed Web of Science ®Google Scholar
• Ribeiro SM, Poczatek M, Schultz-Cherry S, et al. The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-β. J Biol Chem. 1999;274(19):13586–13593. doi: 10.1074/jbc.274.19.13586
   PubMed Web of Science ®Google Scholar
• Cucoranu I, Clempus R, Dikalova A, et al. NAD(P)H oxidase 4 mediates transforming growth factor-β1–Induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res. 2005;97(9):900–907. doi: 10.1161/01.RES.0000187457.24338.3D
   PubMed Web of Science ®Google Scholar
• Desmouliere A, Geinoz A, Gabbiani F, et al. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Bio. 1993;122(1):103–11. doi: 10.1083/jcb.122.1.103
   PubMed Web of Science ®Google Scholar
• Pearson CA, Pearson D, Shibahara S, et al. Tenascin: cDNA cloning and induction by TGF-beta. EMBO J. 1988;7(10):2977–82. doi: 10.1002/j.1460-2075.1988.tb03160.x
   PubMed Web of Science ®Google Scholar
• Horiuchi K, Amizuka N, Takeshita S, et al. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor β. J Bone Miner Res. 1999;14(7):1239–1249. doi: 10.1359/jbmr.1999.14.7.1239
   PubMed Web of Science ®Google Scholar
• Chen MM, Lam A, Abraham JA, et al. CTGF expression is induced by TGF- β in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J Mol Cell Cardiol. 2000;32(10):1805–1819. doi: 10.1006/jmcc.2000.1215
   PubMed Web of Science ®Google Scholar
• Eghbali M, Tomek R, Sukhatme VP, et al. Differential effects of transforming growth factor-beta 1 and phorbol myristate acetate on cardiac fibroblasts. Regulation of fibrillar collagen mRnas and expression of early transcription factors. Circ Res. 1991;69(2):483–90. doi: 10.1161/01.RES.69.2.483
   PubMed Web of Science ®Google Scholar
• Dobaczewski M, Bujak M, Li N, et al. Smad3 signaling critically regulates fibroblast phenotype and function in healing myocardial infarction. Circ Res. 2010;107(3):418–28. doi: 10.1161/CIRCRESAHA.109.216101
   PubMed Web of Science ®Google Scholar
• Chua CC, Chua BH, Zhao ZY, et al. Effect of growth factors on collagen metabolism in cultured human heart fibroblasts. Connect Tissue Res. 1991;26(4):271–281. doi: 10.3109/03008209109152444
   PubMed Web of Science ®Google Scholar
• Bujak M, Ren G, Kweon HJ, et al. Essential role of Smad3 in Infarct healing and in the pathogenesis of cardiac remodeling. Circulation. 2007;116(19):2127–38. doi: 10.1161/CIRCULATIONAHA.107.704197
   PubMed Web of Science ®Google Scholar
• Kong P, Shinde AV, Su Y, et al. Opposing actions of fibroblast and cardiomyocyte Smad3 signaling in the infarcted myocardium. Circulation. 2018;137(7):707–24. doi: 10.1161/CIRCULATIONAHA.117.029622
   PubMed Web of Science ®Google Scholar
• Russo I, Cavalera M, Huang S, et al. Protective effects of activated myofibroblasts in the pressure-overloaded myocardium are mediated through smad-dependent activation of a matrix-preserving program. Circ Res. 2019;124(8):1214–27. doi: 10.1161/CIRCRESAHA.118.314438
   PubMed Web of Science ®Google Scholar
• Huang S, Chen B, Su Y, et al. Distinct roles of myofibroblast-specific Smad2 and Smad3 signaling in repair and remodeling of the infarcted heart. J Mol Cell Cardiol. 2019;132:84–97. doi: 10.1016/j.yjmcc.2019.05.006
   PubMed Web of Science ®Google Scholar
• Ikeuchi M, Tsutsui H, Shiomi T, et al. Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res. 2004;64(3):526–535. doi: 10.1016/j.cardiores.2004.07.017
   PubMed Web of Science ®Google Scholar
• Okada H, Takemura G, Kosai K, et al. Postinfarction gene therapy against transforming growth factor-β signal modulates infarct tissue dynamics and attenuates left ventricular remodeling and heart failure. Circulation. 2005;111(19):2430–2437. doi: 10.1161/01.CIR.0000165066.71481.8E
   PubMed Web of Science ®Google Scholar
• Baxter GF, Mocanu MM, Brar BK, et al. Cardioprotective effects of transforming growth factor-β1 during early reoxygenation or reperfusion are mediated by p42/p44 MAPK. J Cardiovasc Pharmacol. 2001;38(6):930–939. doi: 10.1097/00005344-200112000-00015
   PubMed Web of Science ®Google Scholar
• Rainer PP, Hao S, Vanhoutte D, et al. Cardiomyocyte-specific transforming growth factor β suppression blocks neutrophil infiltration, augments multiple cytoprotective cascades, and reduces early mortality after myocardial infarction. Circ Res. 2014;114(8):1246–1257. doi: 10.1161/CIRCRESAHA.114.302653
   PubMed Web of Science ®Google Scholar
• Chen W. TGF-β regulation of T cells. Annu Rev Immunol. 2023;41(1):483–512. doi: 10.1146/annurev-immunol-101921-045939
   PubMedGoogle Scholar
• Travis MA, Sheppard D. TGF-β activation and function in immunity. Annu Rev Immunol. 2014;32(1):51–82. doi: 10.1146/annurev-immunol-032713-120257
   PubMedGoogle Scholar
• Chen B, Li R, Hernandez SC, et al. Differential effects of Smad2 and Smad3 in regulation of macrophage phenotype and function in the infarcted myocardium. J Mol Cell Cardiol. 2022;171:1–15. doi: 10.1016/j.yjmcc.2022.06.009
   PubMed Web of Science ®Google Scholar
• Weirather J, Hofmann UD, Beyersdorf N, et al. Foxp3+ CD4+ T cells improve healing after myocardial infarction by modulating monocyte/macrophage differentiation. Circ Res. 2014;115(1):55–67. doi: 10.1161/CIRCRESAHA.115.303895
   PubMed Web of Science ®Google Scholar
• Saxena A, Dobaczewski M, Rai V, et al. Regulatory T cells are recruited in the infarcted mouse myocardium and may modulate fibroblast phenotype and function. Am J Physiol Heart Circ Physiol. 2014;307(8):H1233–42. doi: 10.1152/ajpheart.00328.2014
   PubMed Web of Science ®Google Scholar
• Blanton RM, Carrillo-Salinas FJ, Alcaide P. T-cell recruitment to the heart: friendly guests or unwelcome visitors? Am J Physiol Heart Circ Physiol. 2019;317(1):H124–H40. doi: 10.1152/ajpheart.00028.2019
   PubMed Web of Science ®Google Scholar
• Pepper MS. Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev. 1997;8(1):21–43. doi: 10.1016/S1359-6101(96)00048-2
   PubMedGoogle Scholar
• Zhang Y, Yang X. The Roles of TGF-beta Signaling in Cerebrovascular Diseases. Front Cell Dev Biol. 2020;8:567682. doi: 10.3389/fcell.2020.567682
   PubMed Web of Science ®Google Scholar
• Pardali E, ten Dijke P. Transforming growth factor-beta signaling and tumor angiogenesis. Front Biosci (Landmark Ed). 2009;14(1):4848–4861. doi: 10.2741/3573
   PubMedGoogle Scholar
• Walshe TE, Dole VS, Maharaj AS, et al. Inhibition of VEGF or TGF-β signaling activates endothelium and increases leukocyte rolling. Arterioscler Thromb Vasc Biol. 2009;29(8):1185–1192. doi: 10.1161/ATVBAHA.109.186742
   PubMed Web of Science ®Google Scholar
• Frangogiannis NG, Mendoza LH, Lewallen M, et al. Induction and suppression of interferon-inducible protein 10 in reperfused myocardial infarcts may regulate angiogenesis. FASEB J. 2001;15(8):1428–1430. doi: 10.1096/fj.00-0745fje
   PubMedGoogle Scholar
• Chen S, Crawford M, Day RM, et al. RhoA modulates smad signaling during transforming growth factor-β-induced smooth muscle differentiation. J Biol Chem. 2006;281(3):1765–1770. doi: 10.1074/jbc.M507771200
   PubMed Web of Science ®Google Scholar
• Mao X, Debenedittis P, Sun Y, et al. Vascular smooth muscle cell Smad4 gene is important for mouse vascular development. Arterioscler Thromb Vasc Biol. 2012;32(9):2171–7. doi: 10.1161/ATVBAHA.112.253872
   PubMed Web of Science ®Google Scholar
• Rolle IG, Crivellari I, Zanello A, et al. Heart failure impairs the mechanotransduction properties of human cardiac pericytes. J Mol Cell Cardiol. 2021;151:15–30. doi: 10.1016/j.yjmcc.2020.10.016
   PubMed Web of Science ®Google Scholar
• Ren G, Michael LH, Entman ML, et al. Morphological characteristics of the microvasculature in healing myocardial infarcts. J Histochem Cytochem. 2002;50(1):71–9. doi: 10.1177/002215540205000108
   PubMed Web of Science ®Google Scholar
• Dobaczewski M, Akrivakis S, Nasser K, et al. Vascular mural cells in healing canine myocardial infarcts. J Histochem Cytochem. 2004;52(8):1019–29. doi: 10.1369/jhc.3A6210.2004
   PubMed Web of Science ®Google Scholar
• Alex L, Frangogiannis NG. Pericytes in the infarcted heart. Vasc Biol. 2019;1(1):H23–H31. doi: 10.1530/VB-19-0007
   PubMedGoogle Scholar
• Zymek P, Bujak M, Chatila K, et al. The role of platelet-derived growth factor signaling in healing myocardial infarcts. J Am Coll Cardiol. 2006;48(11):2315–23. doi: 10.1016/j.jacc.2006.07.060
   PubMed Web of Science ®Google Scholar
• Quijada P, Park S, Zhao P, et al. Cardiac pericytes mediate the remodeling response to myocardial infarction. J Clin Invest. 2023;133(10). doi: 10.1172/JCI162188
   PubMed Web of Science ®Google Scholar
• Alex L, Tuleta I, Hernandez SC, et al. Cardiac Pericytes Acquire a Fibrogenic Phenotype and Contribute to Vascular Maturation After Myocardial Infarction. Circulation. 2023;148(11):882–98. doi: 10.1161/CIRCULATIONAHA.123.064155
   PubMed Web of Science ®Google Scholar
• Huynh LK, Hipolito CJ, Ten Dijke P. A perspective on the development of TGF-β inhibitors for cancer treatment. Biomolecules. 2019;9(11):743. doi: 10.3390/biom9110743
   PubMed Web of Science ®Google Scholar
• Akhurst RJ. Targeting TGF-β signaling for therapeutic gain. Cold Spring Harb Perspect Biol. 2017;9(10):a022301.
   PubMed Web of Science ®Google Scholar
• Lachapelle P, Li M, Douglass J, et al. Safer approaches to therapeutic modulation of TGF-beta signaling for respiratory disease. Pharmacol Ther. 2018;187:98–113. doi: 10.1016/j.pharmthera.2018.02.010
   PubMed Web of Science ®Google Scholar
• Anderton MJ, Mellor HR, Bell A, et al. Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol Pathol. 2011;39(6):916–24. doi: 10.1177/0192623311416259
   PubMed Web of Science ®Google Scholar
• Stauber AJ, Credille KM, Truex LL, et al. Nonclinical safety evaluation of a transforming growth factor beta receptor I kinase inhibitor in Fischer 344 rats and beagle dogs. J Clin Pract. 2014;4(3). doi: 10.4172/2161-0495.196
   Google Scholar
• Morris JC, Tan AR, Olencki TE, et al. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS One. 2014;9(3):e90353. doi: 10.1371/journal.pone.0090353
   PubMed Web of Science ®Google Scholar
• Kovacs RJ, Maldonado G, Azaro A, et al. Cardiac safety of TGF-β receptor I kinase inhibitor LY2157299 monohydrate in cancer patients in a first-in-human dose study. Cardiovasc Toxicol. 2015;15(4):309–323. doi: 10.1007/s12012-014-9297-4
   PubMed Web of Science ®Google Scholar
• Kosmidou I, Redfors B, Selker HP, et al. Infarct size, left ventricular function, and prognosis in women compared to men after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: results from an individual patient-level pooled analysis of 10 randomized trials. Eur Heart J. 2017;38(21):1656–63. doi: 10.1093/eurheartj/ehx159
   PubMed Web of Science ®Google Scholar
• Traub J, Schurmann P, Schmitt D, et al. Features of metabolic syndrome and inflammation independently affect left ventricular function early after first myocardial infarction. Int J Cardiol. 2023;370:43–50. doi: 10.1016/j.ijcard.2022.10.142
   PubMed Web of Science ®Google Scholar
• Uusimaa P, Risteli J, Niemela M, et al. Collagen scar formation after acute myocardial infarction: relationships to infarct size, left ventricular function, and coronary artery patency. Circulation. 1997;96(8):2565–72. doi: 10.1161/01.CIR.96.8.2565
   PubMed Web of Science ®Google Scholar
• Frantz S, Hu K, Adamek A, et al. Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol. 2008;103(5):485–92. doi: 10.1007/s00395-008-0739-7
   PubMed Web of Science ®Google Scholar
• Frangogiannis NG. Why animal model studies are lost in translation. J Cardiovasc Aging. 2022;2. doi: 10.20517/jca.2022.10
   PubMedGoogle Scholar
• Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol. 2014;11(5):255–65. doi: 10.1038/nrcardio.2014.28
   PubMed Web of Science ®Google Scholar
• Khalil H, Kanisicak O, Prasad V, et al. Fibroblast-specific TGF-β–Smad2/3 signaling underlies cardiac fibrosis. J Clin Invest. 2017;127(10):3770–3783. doi: 10.1172/JCI94753
   PubMed Web of Science ®Google Scholar
• Tuleta I, Frangogiannis NG. Fibrosis of the diabetic heart: clinical significance, molecular mechanisms, and therapeutic opportunities. Adv Drug Deliv Rev. 2021;176:113904. doi: 10.1016/j.addr.2021.113904
   PubMed Web of Science ®Google Scholar
• Derangeon M, Montnach J, Cerpa CO, et al. Transforming growth factor β receptor inhibition prevents ventricular fibrosis in a mouse model of progressive cardiac conduction disease. Cardiovasc Res. 2017;113(5):464–474. doi: 10.1093/cvr/cvx026
   PubMed Web of Science ®Google Scholar
• Biernacka A, Frangogiannis NG. Aging and cardiac fibrosis. Aging Dis. 2011;2:158–173.
   PubMed Web of Science ®Google Scholar
• Sano S, Horitani K, Ogawa H, et al. Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality. Science. 2022;377(6603):292–7. doi: 10.1126/science.abn3100
   PubMed Web of Science ®Google Scholar
• Diez J, Gonzalez A, Kovacic JC. Myocardial interstitial fibrosis in nonischemic heart disease, part 3/4: JACC focus seminar. J Am Coll Cardiol. 2020;75(17):2204–18. doi: 10.1016/j.jacc.2020.03.019
   PubMed Web of Science ®Google Scholar
• Matsa E, Sallam K, Wu JC. Cardiac stem cell biology: glimpse of the past, present, and future. Circ Res. 2014;114(1):21–7. doi: 10.1161/CIRCRESAHA.113.302895
   PubMed Web of Science ®Google Scholar
• Laflamme MA, Murry CE. Heart regeneration. Nature. 2011;473(7347):326–35. doi: 10.1038/nature10147
   PubMed Web of Science ®Google Scholar
• Heallen TR, Kadow ZA, Kim JH, et al. Stimulating cardiogenesis as a treatment for Heart failure. Circ Res. 2019;124(11):1647–57. doi: 10.1161/CIRCRESAHA.118.313573
   PubMed Web of Science ®Google Scholar
• Karbassi E, Fenix A, Marchiano S, et al. Cardiomyocyte maturation: advances in knowledge and implications for regenerative medicine. Nat Rev Cardiol. 2020;17(6):341–59. doi: 10.1038/s41569-019-0331-x
   PubMed Web of Science ®Google Scholar
• Behfar A, Zingman LV, Hodgson DM, et al. Stem cell differentiation requires a paracrine pathway in the heart. FASEB J. 2002;16(12):1558–66. doi: 10.1096/fj.02-0072com
   PubMed Web of Science ®Google Scholar
• Goumans MJ, de Boer TP, Smits AM, et al. TGF-β1 induces efficient differentiation of human cardiomyocyte progenitor cells into functional cardiomyocytes in vitro. Stem Cell Res. 2007;1(2):138–149. doi: 10.1016/j.scr.2008.02.003
   PubMed Web of Science ®Google Scholar
• Chablais F, Jazwinska A. The regenerative capacity of the zebrafish heart is dependent on TGFβ signaling. Development. 2012;139(11):1921–1930. doi: 10.1242/dev.078543
   PubMed Web of Science ®Google Scholar
• Chen WP, Liu YH, Ho YJ, et al. Pharmacological inhibition of TGFβ receptor improves Nkx2.5 cardiomyoblast-mediated regeneration. Cardiovasc Res. 2015;105(1):44–54. doi: 10.1093/cvr/cvu229
   PubMed Web of Science ®Google Scholar
• Mohamed TMA, Ang YS, Radzinsky E, et al. Regulation of cell cycle to stimulate adult cardiomyocyte proliferation and cardiac regeneration. Cell. 2018;173(1):104–16 e12. doi: 10.1016/j.cell.2018.02.014
   PubMed Web of Science ®Google Scholar
• Willems E, Cabral-Teixeira J, Schade D, et al. Small molecule-mediated TGF-β type II receptor degradation promotes cardiomyogenesis in embryonic stem cells. Cell Stem Cell. 2012;11(2):242–252. doi: 10.1016/j.stem.2012.04.025
   PubMed Web of Science ®Google Scholar
• Keepers B, Liu J, Qian L. What’s in a cardiomyocyte – and how do we make one through reprogramming? Biochim Biophys Acta, Mol Cell Res. 2020;1867(3):118464. doi: 10.1016/j.bbamcr.2019.03.011
   PubMed Web of Science ®Google Scholar
• Wang Q, Spurlock B, Liu J, et al. Fibroblast reprogramming in cardiac repair. JACC Basic Transl Sci. 2023;9(1):145–160. doi: 10.1016/j.jacbts.2023.06.012
   PubMedGoogle Scholar
• Riching AS, Danis E, Zhao Y, et al. Suppression of canonical TGF-beta signaling enables GATA4 to interact with H3K27me3 demethylase JMJD3 to promote cardiomyogenesis. J Mol Cell Cardiol. 2020;153:44–59. doi: 10.1016/j.yjmcc.2020.12.005
   PubMed Web of Science ®Google Scholar
• Yamakawa H, Ieda M. Cardiac regeneration by direct reprogramming in this decade and beyond. Inflamm Regen. 2021;41(1):20. doi: 10.1186/s41232-021-00168-5
   PubMed Web of Science ®Google Scholar